Long-term therapy in COPD: any evidence of adverse effect on bone?

Arnulf Langhammer1, Siri Forsmo2, Unni Syversen3,41HUNT Research Centre, Department of Public Health and General Practice, Norwegian University of Science and Technology (NTNU), Verdal, Norway; 2Department of Public Health and General Practice, NTNU, Trondheim, Norway; 3Department of Cancer Research...

Full description

Bibliographic Details
Main Authors: Arnulf Langhammer, Siri Forsmo, Unni Syversen
Format: Article
Language:English
Published: Dove Medical Press 2009-09-01
Series:International Journal of COPD
Online Access:http://www.dovepress.com/long-term-therapy-in-copd-any-evidence-of-adverse-effect-on-bone-a3590
id doaj-65082b13444444efa86eb7792acaf6c8
record_format Article
spelling doaj-65082b13444444efa86eb7792acaf6c82020-11-24T23:41:32ZengDove Medical PressInternational Journal of COPD1176-91061178-20052009-09-012009default365380Long-term therapy in COPD: any evidence of adverse effect on bone?Arnulf LanghammerSiri ForsmoUnni SyversenArnulf Langhammer1, Siri Forsmo2, Unni Syversen3,41HUNT Research Centre, Department of Public Health and General Practice, Norwegian University of Science and Technology (NTNU), Verdal, Norway; 2Department of Public Health and General Practice, NTNU, Trondheim, Norway; 3Department of Cancer Research and Molecular Medicine, NTNU, Trondheim, Norway; 4Department of Endocrinology, St. Olav’s University Hospital, Trondheim, NorwayAbstract: Patients with COPD have high risk for osteoporosis and fractures. Hip and vertebral fractures might impair mobility, and vertebral fractures further reduce lung function. This review discusses the evidence of bone loss due to medical treatment opposed to disease severity and risk factors for COPD, and therapeutic options for the prevention and treatment of osteoporosis in these patients. A review of the English-language literature was conducted using the MEDLINE database until June 2009. Currently used bronchodilators probably lack adverse effect on bone. Oral corticosteroids (OCS) increase bone resorption and decrease bone formation in a dose response relationship, but the fracture risk is increased more than reflected by bone densitometry. Inhaled corticosteroids (ICS) have been associated with both increased bone loss and fracture risk. This might be a result of confounding by disease severity, but high doses of ICS have similar effects as equipotent doses of OCS. The life-style factors should be modified, use of regular OCS avoided and use of ICS restricted to those with evidenced effect and probably kept at moderate doses. The health care should actively reveal risk factors, include bone densitometry in fracture risk evaluation, and give adequate prevention and treatment for osteoporosis.Keywords: COPD, corticosteroids, bronchodilators, bone mineral density, osteoporosis, fractures http://www.dovepress.com/long-term-therapy-in-copd-any-evidence-of-adverse-effect-on-bone-a3590
collection DOAJ
language English
format Article
sources DOAJ
author Arnulf Langhammer
Siri Forsmo
Unni Syversen
spellingShingle Arnulf Langhammer
Siri Forsmo
Unni Syversen
Long-term therapy in COPD: any evidence of adverse effect on bone?
International Journal of COPD
author_facet Arnulf Langhammer
Siri Forsmo
Unni Syversen
author_sort Arnulf Langhammer
title Long-term therapy in COPD: any evidence of adverse effect on bone?
title_short Long-term therapy in COPD: any evidence of adverse effect on bone?
title_full Long-term therapy in COPD: any evidence of adverse effect on bone?
title_fullStr Long-term therapy in COPD: any evidence of adverse effect on bone?
title_full_unstemmed Long-term therapy in COPD: any evidence of adverse effect on bone?
title_sort long-term therapy in copd: any evidence of adverse effect on bone?
publisher Dove Medical Press
series International Journal of COPD
issn 1176-9106
1178-2005
publishDate 2009-09-01
description Arnulf Langhammer1, Siri Forsmo2, Unni Syversen3,41HUNT Research Centre, Department of Public Health and General Practice, Norwegian University of Science and Technology (NTNU), Verdal, Norway; 2Department of Public Health and General Practice, NTNU, Trondheim, Norway; 3Department of Cancer Research and Molecular Medicine, NTNU, Trondheim, Norway; 4Department of Endocrinology, St. Olav’s University Hospital, Trondheim, NorwayAbstract: Patients with COPD have high risk for osteoporosis and fractures. Hip and vertebral fractures might impair mobility, and vertebral fractures further reduce lung function. This review discusses the evidence of bone loss due to medical treatment opposed to disease severity and risk factors for COPD, and therapeutic options for the prevention and treatment of osteoporosis in these patients. A review of the English-language literature was conducted using the MEDLINE database until June 2009. Currently used bronchodilators probably lack adverse effect on bone. Oral corticosteroids (OCS) increase bone resorption and decrease bone formation in a dose response relationship, but the fracture risk is increased more than reflected by bone densitometry. Inhaled corticosteroids (ICS) have been associated with both increased bone loss and fracture risk. This might be a result of confounding by disease severity, but high doses of ICS have similar effects as equipotent doses of OCS. The life-style factors should be modified, use of regular OCS avoided and use of ICS restricted to those with evidenced effect and probably kept at moderate doses. The health care should actively reveal risk factors, include bone densitometry in fracture risk evaluation, and give adequate prevention and treatment for osteoporosis.Keywords: COPD, corticosteroids, bronchodilators, bone mineral density, osteoporosis, fractures
url http://www.dovepress.com/long-term-therapy-in-copd-any-evidence-of-adverse-effect-on-bone-a3590
work_keys_str_mv AT arnulflanghammer longtermtherapyincopdanyevidenceofadverseeffectonbone
AT siriforsmo longtermtherapyincopdanyevidenceofadverseeffectonbone
AT unnisyversen longtermtherapyincopdanyevidenceofadverseeffectonbone
_version_ 1725506778365427712